KENDALL SYMS: Open Payments
NPI 1467102004 · SPARTANBURG, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,921 in 164 payments from 23 companies in 2025. Trend: 2023 $0 · 2024 $2,076 · 2025 $2,921
Food & beverage: $2,554Education: $367
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 53 | $635 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 12 | $239 |
| UCB, Inc. | 10 | $211 |
| Janssen Biotech, Inc. | 7 | $208 |
| Incyte Corporation | 10 | $190 |
| LEO Pharma Inc. | 8 | $164 |
| Amgen Inc. | 6 | $162 |
| Galderma Laboratories, L.P. | 14 | $148 |
| E.R. Squibb & Sons, L.L.C. | 7 | $137 |
| Novartis Pharmaceuticals Corporation | 6 | $121 |
Products named: RINVOQ, DUPIXENT, SKYRIZI, Bimzelx, TREMFYA, ILUMYA, OPZELURA, ADBRY.
Industry payments across SC — which companies pay providers there.
